Inhibrx Biosciences reported total assets of $154.22M and total liabilities of $207.20M for the quarter ended Jun 2026, down 36.4% year over year. This balance sheet covers 12 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Current Assets | ||||||||||||
| Cash & EquivalentsCash & Equiv. | 277.92M | 226.90M | 196.33M | 152.60M | 216.52M | 186.60M | 153.10M | 124.22M | 133.34M | |||
| Receivables - NetNet Receivables | 0.78M | 0.27M | 0.67M | 0.20M | 0.21M | 0.24M | 0.11M | 0.20M | ||||
| Receivables - OtherOther Receivables | 0.61M | 0.61M | 0.95M | -0.77M | -0.14M | 0.73M | 0.73M | -0.71M | 0.13M | |||
| Receivables | 1.39M | 1.22M | -0.10M | 0.06M | 0.21M | 0.97M | 0.84M | -0.51M | ||||
| Prepaid Assets | 16.66M | 13.81M | 9.99M | 7.38M | 6.65M | 6.43M | 7.50M | 8.44M | 8.74M | |||
| Current Assets | 295.36M | 242.06M | 207.45M | 160.40M | 223.39M | 193.96M | 161.42M | 132.83M | 142.21M | |||
| Non-Current Assets | ||||||||||||
| Property, Plant & Equipment (Net) | 6.42M | 7.61M | 6.88M | 6.20M | 5.55M | 4.88M | 4.31M | 3.73M | 2.69M | |||
| Other Non-Current Assets | 3.16M | 6.75M | 6.71M | 6.83M | 6.80M | 6.81M | 5.74M | 4.38M | 4.77M | |||
| Non-Current Assets | 12.54M | 16.36M | 15.12M | 20.37M | 19.25M | 18.15M | 16.05M | 13.65M | 12.01M | |||
| Assets | 307.89M | 258.42M | 222.56M | 180.77M | 242.64M | 212.12M | 177.47M | 146.48M | 154.22M | |||
| Liabilities | ||||||||||||
| Current Liabilities | ||||||||||||
| Accounts Payables | 10.95M | 13.02M | 12.37M | 9.24M | 8.89M | 8.29M | 6.77M | 5.94M | 9.80M | |||
| Payables | 10.95M | 13.02M | 12.37M | 9.24M | 8.89M | 8.29M | 6.77M | 5.94M | 9.80M | |||
| Accumulated Expenses | 43.30M | 23.86M | 29.89M | 29.89M | 32.77M | 28.48M | 26.96M | 25.53M | 15.77M | |||
| Current Leases | 2.06M | 2.17M | 1.83M | 1.59M | 1.97M | 2.17M | 2.25M | 2.33M | 2.49M | |||
| Total Current Liabilities | 56.31M | 39.05M | 44.09M | 40.73M | 43.64M | 38.94M | 35.98M | 33.80M | 28.06M | |||
| Non-Current Liabilities | ||||||||||||
| Non-Current Debt | 206.97M | 98.65M | 99.28M | 99.92M | 100.56M | 176.28M | ||||||
| Operating Leases | 3.17M | 2.17M | 1.83M | 8.05M | 7.88M | 7.51M | 6.99M | 4.13M | 5.34M | |||
| Total Liabilities | 24.81M | -129.59M | 264.39M | -11.57M | 39.05M | 44.09M | 47.18M | 148.20M | 143.56M | 140.64M | 138.49M | 207.20M |
| Shareholder's Equity | ||||||||||||
| Total Debt | 206.97M | 98.65M | 99.28M | 99.92M | 100.56M | 176.28M | ||||||
| Common Equity | -24.81M | 129.59M | 43.50M | 11.57M | 219.37M | 178.47M | 133.58M | 94.44M | 68.56M | 36.83M | 7.99M | -52.98M |
| Liabilities and Shareholders Equity | 307.89M | 258.42M | 222.56M | 180.77M | 242.64M | 212.12M | 177.47M | 146.48M | 154.22M | |||
| Retained Earnings | 657.23M | 233.77M | 236.73M | 239.72M | 243.88M | 246.66M | 250.18M | 254.18M | -316.30M |